Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system

Anticancer Research

Volumn 31, Issue 7, 2011, Pages 2505-2510

  Morisaki, Takashi ^a   Onishi, Hideya ^b   Koya, Norihiro ^a   Kiyota, Akifumi ^a   Tanaka, Hiroto ^a   Umebayashi, Masayo ^a   Ogino, Toshitatsu ^b   Nagamatsu, Iori ^b   Katano, Mitsuo ^b  

^a Fukuoka General Cancer Clinic   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Gemcitabine; HCC; Immunotherapy; MICA; MICB; NKG2D

Indexed keywords

GEMCITABINE; HLA A ANTIGEN; HLA B ANTIGEN; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2D;

ARTICLE; BIOASSAY; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DRUG CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELLS, CULTURED; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; DEOXYCYTIDINE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERLEUKIN-2; LIVER NEOPLASMS; MONOCYTES, ACTIVATED KILLER; MUROMONAB-CD3; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECOMBINANT PROTEINS;

EID: 79961185621     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. + T lymphocytes) in the control of human tumors. Cancer Immunol Immunother 58: 801-808, 2009.
2. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, Cocco L and Vitale M: NK cells and cancer. J Immunol 178: 4011-4016, 2007. (Pubitemid 46492347)
3. Rosenberg SA, Restifo NP, Yang JC, Morgan RA and Dudley ME: Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299-308, 2008. (Pubitemid 351430867)
4. Sutlu T and Alici E: Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 266: 154-181, 2009.
5. Disis ML, Bernhard H and Jaffee EM: Use of tumor-responsive T-cells as cancer treatment. Lancet 373: 673-683, 2009.
6. Nausch N and Cerwenka A: NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958, 2008.
7. Mistry AR and O'Callaghan CA: Regulation of ligands for the activating receptor NKG2D. Immunology 121: 439-447, 2007. (Pubitemid 47030096)
8. Gasser S and Raulet DH: The DNA damage response arouses the immune system. Cancer Res 66: 3959-3962, 2006.
9. Yang TS, Lin YC, Chen JS, Wang HM and Wang CH: Phase II study of gemcitabine in patients in patients with advanced hepatocellular carcinoma. Cancer 89: 750-756, 2000.
10. Plate JM, Plate AE, Shott S, Bograd S and Harris JE: Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 54: 915-925, 2005. (Pubitemid 40991334)
11. Nowak AK, Robinson BW and Lake RA: Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 62: 2353-2358, 2002.
12. Bauer C, Bauernfeind F, Sterzik A, Orban M, Schnurr M, Lehr HA, Endres S, Eigler A and Dauer M: Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut 56: 1275-1282, 2007. (Pubitemid 47300430)
13. Wang X, Cai J, Zhong H, Denham SA and Terasaki PI: Screening of high cytotoxic tumor killer cells using a sensitive adherent target detachment assay. J Immunol Methods 295: 57-65, 2004.
14. Zhou Q, Guo AL. Xu CR, An SJ, Wang Z, Yang SQ and Wu YL: A dendritic cell-based tumor vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro. Clin Exp Immunol 153: 392-400, 2008.
15. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A and Salih HR: Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65: 6321-6329, 2005. (Pubitemid 40994418)
16. Zwirner NW, Fuertes MB, Girart MV, Domaica CI, and Rossi LE: Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system. Cytokine Growth Factor Rev 18: 159-170, 2007. (Pubitemid 46420551)
17. + T-cells. Blood 103: 3065-3072, 2004.
18. + T-cells and NK cells. J Immunol 175: 7819-7828, 2005. (Pubitemid 41798342)